AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia,Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance Thomas O’Hare, William C. Shakespeare,et al. Cancer Cell 2009 November 6;16(5): 401–412
Discoveryof3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)-methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant Chester A. Metcalf, Raji Sundaramoorthi, et al. J. Med. Chem 2010;53:4701–4719
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML EllenWeisberg,Rosemary Barrett,et al. Drug Resistance Updates 2009;12:81–89